80 related articles for article (PubMed ID: 24432510)
1. Introduction to lymphoproliferative disorders in adults.
Leclair SJ; Ferreira K
Clin Lab Sci; 2013; 26(4):181. PubMed ID: 24432510
[No Abstract] [Full Text] [Related]
2. [Kinetic and immunological considerations on the therapy of immunoproliferative disorders].
Pileri A; Boccadoro M; Conte P
Recenti Prog Med; 1979 Feb; 66(2):103-15. PubMed ID: 375339
[No Abstract] [Full Text] [Related]
3. [The significance of cellular surface markers in lymphoproliferative disorders].
Aderka D; Pinkhas J
Harefuah; 1982 Apr; 102(7):307-10. PubMed ID: 6981541
[No Abstract] [Full Text] [Related]
4. Rituximab with peripheral blood stem cell transplantation in CD20 lymphoproliferative disorders.
Mazza P; Palazzo G; Amurri B; Pricolo G; Prudenzano A; Stani L
Haematologica; 2001 Oct; 86(10):1104-5. PubMed ID: 11602420
[No Abstract] [Full Text] [Related]
5. Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone.
Trappe R; Riess H; Anagnostopoulos I; Neuhaus R; Gärtner BC; Pohl H; Müller HP; Jonas S; Papp-Vary M; Oertel S
Ann Hematol; 2009 Feb; 88(2):167-72. PubMed ID: 18636261
[No Abstract] [Full Text] [Related]
6. [Immunological analysis and experimental immunotherapy for HTLV-I-infected T lymphoproliferative disease in a rat model].
Ohashi T; Hanabuchi S; Kannagi M
Nihon Rinsho Meneki Gakkai Kaishi; 2002 Feb; 25(1):65-9. PubMed ID: 11963182
[No Abstract] [Full Text] [Related]
7. Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia.
D'Arena G; Vigliotti ML; Dell'Olio M; Villa MR; Mantuano S; Scalzulli PR; La Sala A; Abbadessa A; Mastrullo L; Cascavilla N
Eur J Haematol; 2009 Mar; 82(3):235-9. PubMed ID: 19067738
[TBL] [Abstract][Full Text] [Related]
8. Primary nonresponse to anti-cd20 therapy in gastrointestinal posttransplant lymphoproliferative disorder.
Gökçe S; Süoğlu OD; Sökücü S; Gün F; Emiroğlu H; Celik A; Doğan O; Cevikbaş U
J Pediatr Gastroenterol Nutr; 2006 Mar; 42(3):316-20. PubMed ID: 16540802
[No Abstract] [Full Text] [Related]
9. [Immunoglobulin G4-associated to multiorganic lymphoproliferative disease].
Bourlon MT; Chapa M; Chablé Montero F; Hernández Calleros J
Gac Med Mex; 2011; 147(6):545-50. PubMed ID: 22116188
[TBL] [Abstract][Full Text] [Related]
10. The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation.
Pescovitz MD
Pediatr Transplant; 2004 Feb; 8(1):9-21. PubMed ID: 15009836
[TBL] [Abstract][Full Text] [Related]
11. A case of IgG4-positive multiorgan lymphoproliferative syndrome: dramatic perturbations of the CD8-positive T-cell repertoire in peripheral blood.
Tsunoda S; Yachie A; Wakasugi H; Matsushita K; Yamaguchi Y; Kawano M
Scand J Rheumatol; 2010 Nov; 39(6):520-3. PubMed ID: 20858140
[No Abstract] [Full Text] [Related]
12. Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus.
Zaltzman JS; Prasad R; Chun K; Jothy S
Nephrol Dial Transplant; 2005 Aug; 20(8):1748-51. PubMed ID: 15919698
[No Abstract] [Full Text] [Related]
13. Immunosuppressive and immunomodulatory therapy-associated lymphoproliferative disorders.
Bagg A; Dunphy CH
Semin Diagn Pathol; 2013 May; 30(2):102-12. PubMed ID: 23541274
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody therapy for posttransplant lymphoproliferative disorders.
Habermann TM
Liver Transpl; 2000 Sep; 6(5):657-8. PubMed ID: 10980069
[No Abstract] [Full Text] [Related]
15. T-cell post-transplantation lymphoproliferative disorder, a rare and challenging late complication of solid organ transplantation.
Afify Z
Pediatr Transplant; 2008 Sep; 12(6):617-8. PubMed ID: 18346038
[No Abstract] [Full Text] [Related]
16. High-dose methotrexate with citrovorum factor rescue for patients with refractory lymphoproliferative disorders.
Case DC
J Maine Med Assoc; 1980 Dec; 71(12):355-8. PubMed ID: 6970790
[No Abstract] [Full Text] [Related]
17. Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome.
Janić MD; Brasanac CD; Janković JS; Dokmanović BL; Krstovski RN; Kraguljac Kurtović JN
Pediatr Blood Cancer; 2009 Dec; 53(6):1117-9. PubMed ID: 19588524
[TBL] [Abstract][Full Text] [Related]
18. Colonic perforation after rituximab treatment for posttransplant lymphoproliferative disorder.
Kutsch E; Kreiger P; Consolini D; Furuya KN
J Pediatr Gastroenterol Nutr; 2013 Jun; 56(6):e41. PubMed ID: 22395186
[No Abstract] [Full Text] [Related]
19. The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders.
Musto P; D'Auria F
Expert Opin Biol Ther; 2011 May; 11(5):551-7. PubMed ID: 21385115
[TBL] [Abstract][Full Text] [Related]
20. Usefulness and limitations of rituximab in managing patients with lymphoproliferative disorder after heart transplantation.
Senechal M; Demers S; Cantin B; Bourgault C; Leblanc MH; Morin J; Couture C
Exp Clin Transplant; 2012 Oct; 10(5):513-8. PubMed ID: 22747415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
